| Title: |
External validation of the IHS4-55 in a european antibiotic-treated hidradenitis suppurativa cohort |
| Authors: |
van Straalen, Kelsey R.; Tzellos, Thrasyvoulos; Alavi, Afsaneh; Benhadou, Farida; Cuenca-Barrales, Carlos; Daxhelet, Mathilde; Daoud, Mathieu; Efthymiou, Ourania; Giamarellos-Bourboulis, Evangelos J.; Guillem, Philippe; Gulliver, Wayne; Jemec, Gregor B. E.; Katoulis, Alexander; Koenig, Anke; Lazaridou, Elizabeth; Lowes, Michelle A.; Marzano, Angelo V.; Matusiak, Lukasz; Molina-Leyva, Alejandro; Moltrasio, Chiara; Pinter, Andreas; Potenza, Concetta; Prens, Errol P.; Romaní, Jorge; Saunte, Ditte M.; Sayed, Christopher; Skroza, Nevena; Stergianou, Dimitra; Szepietowski, Jacek C.; Trigoni, Anastasia; Vilarrasa, Eva; Kyrgidis, Athanassios; Zouboulis, Christos C.; van der Zee, Hessel H. |
| Contributors: |
van Straalen, Kelsey R.; Tzellos, Thrasyvoulo; Alavi, Afsaneh; Benhadou, Farida; Cuenca-Barrales, Carlo; Daxhelet, Mathilde; Daoud, Mathieu; Efthymiou, Ourania; Giamarellos-Bourboulis, Evangelos J.; Guillem, Philippe; Gulliver, Wayne; Jemec, Gregor B. E.; Katoulis, Alexander; Koenig, Anke; Lazaridou, Elizabeth; Lowes, Michelle A.; Marzano, Angelo V.; Matusiak, Lukasz; Molina-Leyva, Alejandro; Moltrasio, Chiara; Pinter, Andrea; Potenza, Concetta; Prens, Errol P.; Romaní, Jorge; Saunte, Ditte M.; Sayed, Christopher; Skroza, Nevena; Stergianou, Dimitra; Szepietowski, Jacek C.; Trigoni, Anastasia; Vilarrasa, Eva; Kyrgidis, Athanassio; Zouboulis, Christos C.; van der Zee, Hessel H. |
| Publisher Information: |
KARGER; ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND |
| Publication Year: |
2023 |
| Collection: |
Sapienza Università di Roma: CINECA IRIS |
| Subject Terms: |
clinical trial; endpoint; hidradenitis suppurativa; international hidradenitis suppurativa 4; outcome; treatment; validation |
| Description: |
Background: Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 score (IHS4-55). It was validated in datasets of adalimumab and placebo treated HS patients. External validation is an important aspect of clinical outcomes.Objectives: We aimed to externally validate the novel dichotomous IHS4-55 in a non-biologic treated dataset of HS patients.Methods: Data from a previously published European-wide prospective clinical study of antibiotic treatment of HS patients was used to assess the association of IHS4-55 achievement with individual reduction in inflammatory nodules, abscesses and draining tunnels. Moreover, the associations between IHS4-55 positivity and achievement of the minimal clinically important differences (MCID) for Dermatology Life Quality Index (DLQI), numerical rating scale (NRS) Pain, and NRS Pruritus were analyzed.Results: Data was obtained from 283 individual patients, of which 36.4% (103/283) were treated with clindamycin and rifampicin and 63.6% (180/283) with tetracyclines for 12 weeks. Achievers of the IHS4-55 demonstrated a significant reduction the counts of inflammatory nodules, abscesses, and draining tunnels (all p |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/36630943; info:eu-repo/semantics/altIdentifier/wos/WOS:000922644000001; volume:239; issue:3; firstpage:362; lastpage:367; numberofpages:6; journal:DERMATOLOGY; https://hdl.handle.net/11573/1701342 |
| DOI: |
10.1159/000528968 |
| Availability: |
https://hdl.handle.net/11573/1701342; https://doi.org/10.1159/000528968 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.EF118E8C |
| Database: |
BASE |